L
Leslie Cottle
Researcher at Fred Hutchinson Cancer Research Center
Publications - 12
Citations - 1758
Leslie Cottle is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Cabotegravir & Maraviroc. The author has an hindex of 8, co-authored 11 publications receiving 1117 citations. Previous affiliations of Leslie Cottle include University of North Carolina at Chapel Hill & Asociación Civil Impacta Salud y Educación.
Papers
More filters
Journal ArticleDOI
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Leslie Cottle,Xinyi C. Zhang,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Sharlaa Faesen,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Sarah E. Hudelson,Andrew D. Redd,Thomas R. Fleming +35 more
TL;DR: The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners, and was associated with a 93% lower risk of linked partner infection than was delayed ART.
Journal ArticleDOI
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz,Deborah Donnell,Meredith E. Clement,Brett Hanscom,Leslie Cottle,Lara E. Coelho,Robinson Cabello,Suwat Chariyalertsak,Eileen F. Dunne,Ian Frank,Jorge A Gallardo-Cartagena,Aditya H Gaur,Pedro Gonzales,Ha V Tran,Juan C Hinojosa,Esper G Kallas,Colleen F Kelley,Marcelo H. Losso,J Valdez Madruga,Keren Middelkoop,Nittaya Phanuphak,Breno Santos,Omar Sued,Javier Valencia Huamaní,Edgar T. Overton,Shobha Swaminathan,Carlos del Rio,Roy M. Gulick,Paul G. Richardson,Philip Sullivan,Estelle Piwowar-Manning,Mark A. Marzinke,Craig W. Hendrix,Maoji Li,Zhe Wang,Jeanne M. Marrazzo,Eric S. Daar,Aida Asmelash,Todd T. Brown,Peter J. Anderson,Susan H. Eshleman,Marcus Bryan,Cheryl Blanchette,Jonathan Lucas,Christina Psaros,Steven A. Safren,Jeremy Sugarman,Hyman M. Scott,Joseph J. Eron,Sheldon D. Fields,Nirupama Sista,Kailazarid Gomez-Feliciano,Andrea Jennings,Ryan Kofron,Timothy H. Holtz,Katherine Shin,James F. Rooney,Kimberly Y. Smith,William Spreen,David J. Margolis,Alex R. Rinehart,Adeola Adeyeye,Myron S. Cohen,Marybeth McCauley,Beatriz Grinsztejn,Hptn (PopART) Study Team +65 more
TL;DR: In this paper, safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preve...
Journal ArticleDOI
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Raphael J. Landovitz,Sue Li,Beatriz Grinsztejn,Halima Dawood,Albert Y. Liu,Manya Magnus,Mina C. Hosseinipour,Ravindre Panchia,Leslie Cottle,Gordon Chau,Paul G. Richardson,Mark A. Marzinke,Craig W. Hendrix,Susan H. Eshleman,Yinfeng Zhang,Elizabeth E. Tolley,Jeremy Sugarman,Ryan Kofron,Adeola Adeyeye,David N. Burns,Alex R. Rinehart,David Margolis,William Spreen,Myron S. Cohen,Marybeth McCauley,Joseph J. Eron +25 more
TL;DR: In this study, CAB LA was well tolerated at the doses and dosing intervals used and was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test.
Journal ArticleDOI
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Raphael J. Landovitz,Sue Li,Joseph J. Eron,Beatriz Grinsztejn,Halima Dawood,Albert Y. Liu,Manya Magnus,Mina C. Hosseinipour,Ravindre Panchia,Leslie Cottle,Gordon Chau,Paul G. Richardson,Mark A. Marzinke,Susan H. Eshleman,Ryan Kofron,Adeola Adeyeye,David N. Burns,Alex R. Rinehart,David Margolis,Myron S. Cohen,Marybeth McCauley,Craig W. Hendrix +21 more
TL;DR: The clinical significance of the long pharmacokinetic tail of cabotegravir observed in female participants compared with male participants, and those with higher BMI compared with a lower BMI, need to be addressed in future trials.
Journal ArticleDOI
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).
Roy M. Gulick,Timothy J. Wilkin,Ying Q. Chen,Raphael J. Landovitz,K. Rivet Amico,Alicia M. Young,Paul G. Richardson,Mark A. Marzinke,Craig W. Hendrix,Susan H. Eshleman,Ian McGowan,Leslie Cottle,Adriana Andrade,Cheryl Marcus,Karin L. Klingman,Wairimu Chege,Alex R. Rinehart,James F. Rooney,Philip Andrew,Robert A. Salata,Manya Magnus,Jason E. Farley,Albert Y. Liu,Ian Frank,Ken Ho,Jorge Santana,Joanne D. Stekler,Marybeth McCauley,Kenneth H. Mayer +28 more
TL;DR: MVC-containing regimens were safe and well tolerated compared with TDF + FTC and may warrant further study for pre-exposure prophylaxis; this study was not powered for efficacy.